Topical JAK Inhibitor Composition for Skin Permeability and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors used for treating autoimmune diseases have safety hazards due to systemic side effects from oral administration, necessitating a topical formulation with improved penetration and stability.
Innovation Solution
A pharmaceutical composition comprising a JAK inhibitor with specific ratios of a compound, solvent, and transdermal enhancer, including components like polyethylene glycol 400, diethylene glycol monoethyl ether, and oleic acid, to enhance topical delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral JAK inhibitors are used to treat autoimmune diseases, then therapeutic efficacy is improved, but systemic side effects increase
Solution Approach 1:
The invention extracts the active JAK inhibitor compound from systemic circulation and delivers it specifically to the skin through topical formulation. The composition isolates the therapeutic action to the target site (skin) while avoiding systemic distribution, thereby maintaining efficacy for skin autoimmune diseases while eliminating systemic side effects
Solution Approach 2:
The invention applies local quality by creating a topical formulation with specific penetration-enhancing components that enable the JAK inhibitor to act locally on skin tissues. The formulation includes transdermal penetration enhancers and specific solvents that ensure the drug concentrates at the application site rather than distributing systemically, achieving localized therapeutic effect without systemic exposure
2Object-affected harmful factors
If topical formulation is used to reduce systemic side effects, then safety is improved, but penetration efficiency decreases
Solution Approach 1:
The invention introduces transdermal penetration enhancers as intermediary substances that facilitate the passage of JAK inhibitor through the skin barrier. These enhancers (such as fatty acids, alcohols, or surfactants) temporarily modify the skin barrier properties or interact with the drug to improve its permeation, enabling effective topical delivery without systemic side effects
Solution Approach 2:
The invention changes the physical and chemical parameters of the formulation including pH, solvent composition, and penetration enhancer concentration to optimize drug permeation. By adjusting these parameters, the formulation achieves sufficient penetration efficiency through the skin while maintaining localized action and avoiding systemic side effects
3Object-affected harmful factors
If topical formulation is developed, then safety is improved, but formulation stability becomes challenging
Solution Approach 1:
The invention uses composite materials by combining the JAK inhibitor with specific excipients, solvents, and penetration enhancers in a stabilized formulation system. The composite formulation includes stabilizing agents that prevent drug degradation, maintain pH balance, and ensure physical stability, enabling safe topical application with reduced systemic side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves good permeability and stability with reduced side effects, suitable for treating skin autoimmune diseases like alopecia areata and atopic dermatitis.
Implementation Method 1
a transdermal enhancer... to enhance topical delivery and stability... achieves good permeability
Implementation Method 2
35% to 93% of a solvent... including components like polyethylene glycol 400, diethylene glycol monoethyl ether, and oleic acid
Data Source
AI summary
Disclosed are a pharmaceutical composition comprising a JAK inhibitor, a preparation method therefor and use of thereof, and particularly disclosed is a pharmaceutical composition comprising a JAK inhibitor. The pharmaceutical composition comprises the following components: 0.1 wt %-3 wt % of the compound represented by formula (I) or the compound represented by formula (II) or a pharmaceutically acceptable salt thereof, 35 wt %-93 wt % of a solvent, and 5 wt %-63 wt % of a transdermal enhancer. When used as a topical liniment, the pharmaceutical composition of the present invention has good permeability and stability.